期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替罗非班对急性冠状动脉综合征患者介入术后炎症因子的影响 被引量：3

Effect of tirofiban on serum inflammatory factors in patients with acute coronary syndrome after percutaneous coronary intervention
下载PDF
导出
摘要 目的观察替罗非班对急性冠状动脉综合征(acute coronary syndrome,ACS)患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)治疗后血清炎症因子的影响。方法初次确诊为ACS85例,对照组41例,未应用替罗非班;替罗非班组44例,用替罗非班治疗,测定其可溶性CD40配体、高敏C反应蛋白、基质金属蛋白酶-9水平。结果替罗非班试验组血清可溶性CD抗原40配体、高敏C反应蛋白、基质金属蛋白酶-9水平显著低于对照组,差异有统计学意义(P<0.05)。结论ACS患者PCI术后应用替罗非班可明显降低血清炎症因子的水平。 Objectives To observe the effect of tirofiban on serum inflammatory factors in patients with acute coronary syndromes （ACS） after percutaneous coronary intervention （PCI）. Methods Eighty-five cases were diagnosed initially as ACS. All cases were treated with routine medicines, while 44 cases were treated with additional tirofiban. Serum soluble CD40 ligand （sCD40L） , high sensitivity C reaction protein （hs-CRP） and matrix metalloproteinase-9 （MMP-9） were determined by ELISA. Results Serum CD40L, hs-CRP. MMP-9 were decreased more significantly in patients treated with additional tirofiban than in patients treated with routine medicines （P〈0.05）. Conclusions Tirofiban reduces serum inflammatory cytokines in patients with ACS after PCI.
作者 刘鸿涛 曾秋棠 李裕舒 王祥 李大主 毛小波 毛奕
机构地区 荆门市第二人民医院心内科 华中科技大学同济医学院附属协和医院心内科
出处 《岭南心血管病杂志》 2008年第5期324-326,共3页 South China Journal of Cardiovascular Diseases
关键词 急性冠状动脉综合征 替罗非班 可溶性CD40配体 高敏C反应蛋白 基质金属蛋白酶一9 Acute coronary syndromes Tirofiban Soluble CD40 ligand High sensitivity C reaction protein Matrix metalloproteinase-9
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献11

  • 1CHESEBRO J H, ZOLDHELYI P, FUSTER V. Plaque disruption and thrombosis in unstable angina pectoris [ J ]. Am J Cardiol, 1991, 68 (12): 9C-15C.
  • 2陈纪林.冠心病抗血小板治疗的进展(1)血小板在动脉粥样硬化形成和发展中的作用[J].中国循环杂志,2004,19(1):5-6. 被引量：29
  • 3MACH F, SCHONBECK U, SUKHOVA G K, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implication for CD40-CD40 ligand signaling in atherosclerosis [J]. Proc Natl Acad Sci USA, 1997, 94 (15) : 1931-1936.
  • 4HENN V, STEINBACH S, BUCHNER K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelet is temporally limited by eoexpresscd CD40[J]. Blood, 2001, 98 (4): 1047-1054.
  • 5GARLICHS C D, ESKAFI S, RAAZ D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/ CD154 on platelets[J]. Heart, 2001, 86 (3): 649-655.
  • 6WILSON A M, RYAN M C, BOYLE A J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathologen[J]. Int J Cardiol, 2006, 106 (3) : 291-297.
  • 7HEECHEN C, DIMMELER S, HAMM C W, et al. Soluble CD40 ligand in acute coronary syndromes [ J ]. N Engl J Med, 2003, 348 (12): 1104-1111.
  • 8KAI H, IKEDA H, YASUKAWA H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes[Jl. J Am Coll Cardiol, 1998, 32 (2): 368-372.
  • 9NOMOTO K, OGUCHI S, WATANABE I, et al. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1[J]. J Cardiol, 2003, 42 (5): 201-206.
  • 10ZENG B, PRASAN A, FUNG K C, et al. Elevated circulating levels of matrix metalloproteinase-9 and-2 in patients with symptomatic coronary artery disease[J]. Intern Med J, 2005, 35 (6): 331-335.

二级参考文献12

  • 1Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation, 2002,105 : 656-662.
  • 2Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial ( RAPPORT ). Circulation, 1998,98 : 734-741.
  • 3Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344:1895-1903.
  • 4Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346 : 957-966.
  • 5Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blockade on recovery flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infction. Circulation, 1998, 98 : 2695-2701.
  • 6Petronioa AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Euro Heart Journal, 2003, 24: 67-76.
  • 7The RESTORE Investigators. Effects of platelet glycoprotein Ⅱ b/Ⅲ a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96: 1445-1453.
  • 8Lincoff AM. Trial of platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonists during percutaneous coronary revascularization. Am J Cardiol, 1998, 82:36-42.
  • 9Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol, 2004, 94:35-39.
  • 10Gibson CM, Christopher PC, William LD, et al. TIMI frame count : A quantitative method of assessing coronary artery flow. Circulation, 1996,93 : 879-888.

共引文献118

同被引文献21

  • 1方唯一.冠脉复杂病变介入治疗[J].中国心血管病研究,2005,3(7):483-485. 被引量：10
  • 2张燕,刘鹏,李靖.替罗非班对冠心病PCI术中内皮功能障碍影响的研究[J].中国误诊学杂志,2006,6(16):3069-3071. 被引量：8
  • 3卢竞前,洪云飞,杨锋,李易,李建美,吕云,李玉,张荣华.国产替罗非班治疗急性冠脉综合征的临床观察[J].中国心血管病研究,2007,5(5):334-337. 被引量：4
  • 4Bassand JP, Hamm CW. Guidelines for the diagnosis and treatment of non - ST - segment elevation acute coronary syndromes. Eur Heart J, 2007,28 : 1598 - 1660.
  • 5Kimmelstiel C, Badar J,Covic L, et al. Pharmaeodynamies and pharmacokineties of the platelet GP II b/III a inhibitor tirofiban in patients undergoing pereutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res,2005,55 -66.
  • 6Yang YJ,Zhao JL,You SJ,et al. Different effects of tirofiban and aspirin plus clopi - dogrel on myocardial no - reflow in a mini - swine model of acute myocardial infarction and reperfusion. Heart, 2006,92 (8) :1131.
  • 7Sorin J, Brener. The Benefits of Platetet Glycoprotein IIb/IIIa Receptor Inhibition During Primary Percutaneons Coronary Intervention for ST - Segment Elevation Myocardial Infarction, Journal of the American College of Cardiology ,2009,53 ( 18 ) : 1674 - 1676.
  • 8Abbo KM,Dooris M,Glazier S,et al.Features and outcome of no-reflow after percutaneous coronary intervention.Am J Cardiol,1995,75:778-782.
  • 9Henriques JP,Zijlstra F,Ottervanger JP,et al.Incidence and clinical significance of distal embolization during primary angjoplasty for acute myocardial infarction.Eur Heart J,2002,23:1112-1117.
  • 10Valgimigli M,Campo G,Percoco G,et al.Comparison of angioplasty with infusion of tirofiban or abciximab and with im plantation of sirolimus -eluting or uncoated stents for acute myocardial infarction:the MULTISTRATEGY randomized trial.JAMA,2008,299:1788-1799.

引证文献3

二级引证文献12

岭南心血管病杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部